Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

PharmaCyte Biotech (PMCB) Return on Capital Employed (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Return on Capital Employed for 16 consecutive years, with 0.1% as the latest value for Q1 2026.

  • Quarterly Return on Capital Employed rose 4.0% to 0.1% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.1% through Jan 2026, up 4.0% year-over-year, with the annual reading at 0.08% for FY2025, 6.0% up from the prior year.
  • Return on Capital Employed for Q1 2026 was 0.1% at PharmaCyte Biotech, down from 0.09% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.04% in Q1 2022, with the low at 0.15% in Q2 2024.
  • Average Return on Capital Employed over 5 years is 0.09%, with a median of 0.09% recorded in 2023.
  • The sharpest move saw Return on Capital Employed skyrocketed 56bps in 2022, then decreased -6bps in 2024.
  • Over 5 years, Return on Capital Employed stood at 0.08% in 2022, then fell by -5bps to 0.08% in 2023, then crashed by -60bps to 0.13% in 2024, then skyrocketed by 33bps to 0.09% in 2025, then decreased by -15bps to 0.1% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.1%, 0.09%, and 0.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.